Skip to main content

Advertisement

SpringerLink
Log in

Antibody-based therapies for the treatment of brain metastases from HER2-positive breast cancer: time to rethink the importance of the BBB?

  • Letter to the Editor
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

A Rebuttal Letter to this article was published on 30 June 2017

The Original Article was published on 10 May 2017

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Lewis Phillips GD, Nishimura MC, Lacap JA, Kharbanda S, Mai E, Tien J, Malesky K, Williams SP, Marik J, Phillips HS (2017) Trastuzumab uptake and its relation to efficacy in an animal model of HER2-positive breast cancer brain metastasis. Breast Cancer Res Treat. doi:10.1007/s10549-017-4279-4

    PubMed Central  PubMed  Google Scholar 

  2. Kodack DP, Askoxylakis V, Ferraro GB, Sheng Q, Badeaux M, Goel S, Qi X, Shankaraiah R, Cao AZ, Ramjiawan RR, Bezwada D, Patel B, Song Y, Costa C, Naxerova K, Wong C, Kloepper J, Das R, Tam A, Tanboon J, Duda GD, Miller CR, Siegel MB, Anders CK, Sanders M, Estrada MV, Schlegel R, Arteaga CL, Brachtel E, Huang A, Fukumura D, Engelman JA, Jain RK (2017) The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation. Sci Transl Med 9(391):eaal4682

    Article  PubMed  Google Scholar 

  3. Askoxylakis V, Ferraro GB, Kodack DP, Badeaux M, Shankaraiah RC, Seano G, Kloepper J, Vardam T, Martin JD, Naxerova K, Bezwada D, Qi X, Selig MK, Brachtel E, Duda GD, Huang P, Fukumura D, Engelman JA, Jain RK (2015) Preclinical efficacy of ado-trastuzumab emtansine in the brain microenvironment. J Natl Cancer Inst 108(2):djv313

    PubMed Central  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Edwin L. Steele Laboratories, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA

    Vasileios Askoxylakis, David P. Kodack, Gino B. Ferraro & Rakesh K. Jain

Authors
  1. Vasileios Askoxylakis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David P. Kodack
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gino B. Ferraro
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Rakesh K. Jain
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Rakesh K. Jain.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.

Additional information

This letter to the editor refers to the article available at doi: 10.1007/s10549-017-4279-4 and a rebuttal letter to this letter to the editor is available at doi: 10.1007/s10549-017-4352-z.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Askoxylakis, V., Kodack, D.P., Ferraro, G.B. et al. Antibody-based therapies for the treatment of brain metastases from HER2-positive breast cancer: time to rethink the importance of the BBB?. Breast Cancer Res Treat 165, 467–468 (2017). https://doi.org/10.1007/s10549-017-4351-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-017-4351-0

Search

Navigation